Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO

 

• Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving elraglusib/GnP
• Risk of death was reduced by 37% (HR=0.63) in patients treated with elraglusib/GnP
• Data featured as an oral presentation at the ASCO Annual Meeting
• Company plans to engage with FDA in the second half of 2025 to align on a path towards product registration
• Company to host KOL event today at 6:30 pm CDT to discuss 1801 Part 3B results

Event Details:

Date and Time:	Saturday, May 31, 2025, at 6:30 pm CDT
Format:	In-person and via live webcast
Registration:	Click here

A replay of the event will be available on the Investor Relations section of the Actuate website.

https://www.globenewswire.com/news-release/2025/05/31/3091442/0/en/Actuate-Therapeutics-Presents-Topline-Elraglusib-Phase-2-Data-at-ASCO-2025-Annual-Meeting-Trial-Meets-Primary-Endpoint-of-Median-Overall-Survival-and-Doubles-1-Year-Survival-in-Fir.html